Dyadic International (NASDAQ: DYAI), a global leader in cell culture solutions, announced a strategic partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the nutrition, diagnostics, and cell culture sectors. Under the agreement, Proliant will provide Dyadic with $1.5 million upfront to develop high-volume, cost-effective cell culture products. The product is set to debut in the first half of 2025 in the $6 billion serum albumin market.
These animal-free recombinant albumin products will be developed using Dyadic International’s advanced filamentous fungal microbial platforms. Dyadic will also receive a profit share from PHB’s sales of these products. Part of the initial milestone payment will fund commercialization efforts and technology transfer. The partnership will initially focus on launching recombinant human serum albumin products.
Proliant Health and Biologicals, the world’s leading manufacturer of animal-derived proteins, specializes in producing animal extracts and multiple grades of “Fraction V” bovine serum albumin (BSA). Renowned for its unmatched consistency, traceability, and quality, Proliant is the preferred BSA supplier for industries such as in-vitro diagnostics, vaccine production, biopharmaceutical and medical device manufacturing, nutraceuticals, and life science research.
In the June 28, 2024, news release, Dyadic International management expressed enthusiasm about the partnership with Proliant Health and Biologicals (PHB) for producing bovine serum albumin and other cell culture products. This collaboration highlights Dyadic’s strategic move to commercialize products and generate revenue in the alternative protein market in the near future.
Dyadic International’s protein product technology, combined with Proliant Health and Biologicals’ (PHB) strong market position, presents a significant opportunity to co-produce high-quality, cost-effective products at scale. PHB’s management noted a surge in demand for alternative protein sources in the life sciences and diagnostics industries in recent years. This partnership enables PHB to expand its product portfolio to include animal-free proteins and gain access to technology with unlimited innovation potential.
These companies are active in the biotechnology and life sciences sector. Ocular Therapeutix, Inc. (NASDAQ: OCUL) develops treatments for eye diseases and conditions using its proprietary hydrogel technology. Abeona Therapeutics Inc. (NASDAQ: ABEO) focuses on creating gene and cell therapies for life-threatening rare genetic diseases. Geron Corporation (NASDAQ: GERN) is dedicated to developing cancer therapies, specifically targeting telomerase inhibitors. Inovio Pharmaceuticals, Inc. (NASDAQ: INO) specializes in the development of DNA-based immunotherapies and vaccines.
Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors with a safe harbor with regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, and assumptions about future events or performance are not statements of historical fact and may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties that could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor’s investment may be lost or due to the speculative nature of the companies profiled. TheStreetReports (TSR) is responsible for the production and distribution of this content.”TSR” is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security. “TSR” authors, contributors, or its agents, may be compensated for preparing research, video graphics, podcasts and editorial content. “TSR” has not been compensated to produce content related to “Any Companies” appearing herein. As part of that content, readers, subscribers, and everyone viewing this content are expected to read the full disclaimer in our website.
Media Contact
Company Name: The Street Reports
Contact Person: Editor
Email: Send Email
Country: United States
Website: http://www.thestreetreports.com